These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6980497)

  • 1. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H
    Thromb Res; 1982 Apr; 26(1):21-9. PubMed ID: 6980497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent intrinsic prothrombinase activity of human Factor X zymogen: identification with Factor VIII inhibitor bypassing activity (FEIBA).
    Estry DW; Tishkoff GH
    Thromb Res; 1984 Dec; 36(6):549-62. PubMed ID: 6335607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology.
    Lundblad RL; Bergstrom J; De Vreker R; Bray G; Gomperts E; Baker D; Kingdon HS; Mann KG; Hartshorn J; Jenny RJ
    Thromb Haemost; 1998 Nov; 80(5):811-5. PubMed ID: 9843176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated clotting factors in factor IX concentrates.
    Hultin MB
    Blood; 1979 Nov; 54(5):1028-38. PubMed ID: 497395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of factor IX concentrate therapy in hemophilia.
    Hultin MB
    Blood; 1983 Sep; 62(3):677-84. PubMed ID: 6603880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.
    Stern DM; Nawroth PP; Kisiel W; Handley D; Drillings M; Bartos J
    J Clin Invest; 1984 Dec; 74(6):1910-21. PubMed ID: 6439737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Separation of an active substance responsible for the factor VIII inhibitor bypassing activity in Autoplex.
    Fukui H; Fujimura Y; Sugimoto M; Okubo Y; Yoshioka A
    Nihon Ketsueki Gakkai Zasshi; 1985 Feb; 48(1):134-46. PubMed ID: 3873774
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombogenicity of antihemophiliac preparations with factor VIII inhibitor bypassing activity.
    Melewski DJ; Huebschmann J; Tourbaf K; Ambrus CM; Ambrus JL
    J Med; 1981; 12(2-3):89-96. PubMed ID: 6974212
    [No Abstract]   [Full Text] [Related]  

  • 11. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to activated F IX concentrate (FEIBA).
    Stenbjerg S; Jorgensen J
    Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction between factor VIII clotting antigen (VIIICAg) and phospholipid.
    Yoshioka A; Peake IR; Furlong BL; Furlong RA; Giddings JC; Bloom AL
    Br J Haematol; 1983 Sep; 55(1):27-36. PubMed ID: 6411112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of human factor VII by activated factors IX and X.
    Masys DR; Bajaj SP; Rapaport SI
    Blood; 1982 Nov; 60(5):1143-50. PubMed ID: 7126868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII.
    Laurian Y; Girma JP; Lambert T; Meyer D; Larrieu MJ
    Blood; 1984 Feb; 63(2):457-62. PubMed ID: 6419798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombin complex concentrates for clinical use.
    Chandra S; Brummelhuis HG
    Vox Sang; 1981; 41(5-6):257-73. PubMed ID: 6798760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
    Griffith MJ; Breitkreutz L; Trapp H; Briet E; Noyes CM; Lundblad RL; Roberts HR
    J Clin Invest; 1985 Jan; 75(1):4-10. PubMed ID: 3871202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Contribution to the mechanism of the "factor VIII bypassing activity" (FEIBA)-reaction].
    Sander W; Wilms K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):581-7. PubMed ID: 1714863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.